EC Number   |
Application |
Reference |
|---|
   5.1.3.17 | analysis |
assay procedure for heparosan-N-sulfate-glucuronate 5-epimerase, which is based on the use of a two-phase system for liquid scintillation counting |
2291 |
| 5.1.3.17 | diagnostics |
GLCE upregulation plus expression pattern of a panel of six genes, discriminating morphologically different prostate cancer cell subtypes, is a potential marker of aggressive prostate cancer |
749412 |
| 5.1.3.17 | medicine |
in 82-84% of human breast tumors there is either downregulation or loss of D-glucuronyl C5-epimerase mRNA expression and significant decrease of the protein content. In 77% of cases, GLCE expression is decreased also in the normal-appearing tissue surrounding the tumor node but the protein amount is comparable to normal breast tissue |
692657 |
| 5.1.3.17 | medicine |
the anti-tumour effects associated with ectopic GLCE re-expression suggest that it may be a potential tumour-suppressor gene and a possible target for lung cancer diagnosis and treatment |
714635 |
| 5.1.3.17 | medicine |
the enzyme is a candidate molecular marker for advanced prostate cancer |
727266 |
| 5.1.3.17 | synthesis |
the enzyme, coexpressed with 2-O-sulfotransferase in bacteria, can be used for production of bioengineered heparin as a potential substitute for the animal-sourced anticoagulant drug |
746780 |
